Microbot Medical Inc.
HealthcareNASDAQ:MBOT · NASDAQ Capital Market
-$0.04 today
Vol 0.91M · Avg 1.68M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-16.9%
avg 801.0%
ROIC
-18.8%
avg -218.0%
ROA
-16.1%
avg -112.9%
Analysis
ROA is currently the strongest return metric at -16.1% versus its period average of -112.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Harel Gadot | Co-Founder, President, Chief Executive Officer & Chairman | $1.31M | — | 53 | $480,000.00 | 1.05% |
Simon Sharon | Chief Technology Officer & GM of Microbot Israel | $523,672.00 | — | 66 | $105,000.00 | 0.23% |
Juan Diaz-Cartelle | Chief Medical Officer | $497,408.00 | — | 50 | $105,000.00 | 0.23% |
Rachel Vaknin | Chief Financial Officer | $376,080.00 | — | 47 | $105,000.00 | 0.23% |
Christina Bailey | Vice President of Sales | — | — | — | — | — |
Michal Ahuvia | Director of Operations | — | — | — | — | — |
Michael Lytle | Head of Sales Operations & Analytics | — | — | — | — | — |
Allison Rosefort | Vice President of Marketing | — | — | — | — | — |
Naama Moav | Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -55.9% | +53.6% (14yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -55.9% over three years. Forward estimates point to Revenue at +53.6% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$158.38M
Context Therapeutics Inc.
NASDAQ:CNTX
$127.71M
Cardiol Therapeutics Inc.
NASDAQ:CRDL
$115.23M
AVITA Medical, Inc.
NASDAQ:RCEL
$97.14M
Vivani Medical, Inc.
NASDAQ:VANI
$64.99M
Clene Inc.
NASDAQ:CLNN
$60.20M
DocGo Inc.
NASDAQ:DCGO
$57.25M
Zentek Ltd.
ZTEK
$49.15M
InspireMD, Inc.
NSPR
$34.19M
Who manages MBOT?
Microbot Medical Inc. (MBOT) lists 9 active executives. The top listed executive is Rachel Vaknin, Chief Financial Officer.
Are MBOT insiders buying or selling?
Recent insider activity shows net buying of $11.35M.
Explore More
Continue the stock analysis
Jump to another research area for this company.